The Consumer Justice Foundation Alerts the Public of an FDA Boxed Warning Announcement Regarding Adcetris Side Effects and Contraindication That Could Lead to Danger

Share Article

The Consumer Justice Foundation, a for-profit corporation whose Web site URL can be found at, hereby alerts the public of a new FDA Boxed Warning regarding two additional reports of dangerous Adcetris side effects as well as an FDA warning regarding a contraindication regarding the use of Adcetris with a common cancer medication. The team of consumer advocates at the CJF suggesst that those who are using Adcetris should seek the advice of their medical care provider.

The Consumer Justice Foundation, a for-profit corporation that is staffed by a team of professional consumer advocates who provide free online informational resources regarding the use of certain prescription medications, hereby alerts the public of a recent FDA Boxed Warning and contraindication announcement regarding the development of two additional cases of dangerous Adcetris side effects and the potential for danger for consumers who are using Adcetris as well as a popular cancer medication.

Specifically, the FDA issued a warning entitled, “FDA Drug Safety Communication: New Boxed Warning and Contraindication for Adcetris (brentuximab vedotin)” on Friday, January 13. The Boxed warning stated that two additional cases of Adcetris side effects had been reported, and this Adcetris side effect is known as progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death. The symptoms for PML include mood changes and unusual behavior, confusion, loss of memory, speech, vision or walking problems and weakness in one side of the body. In response to these reports of Adcetris side effects, the FDA has announced a Boxed Warning that will appear on containers of Adcetris that warn consumers of the potential for Adcetris side effects.

Adcetris is a medication that’s manufactured by Seattle Genetics, Inc. and it was approved for use in August 2011 to help patients treat conditions that include Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma. The reports of two additional diagnoses of PML in patients who had been using Adcetris have been recent.

In addition, the FDA issued a Contraindication warning regarding the use of Adcetris simultaneously with a medication known as the cancer drug bleomycin due to increased risk of pulmonary (lung) toxicity. This contraindication warning has also been added to the drug label. Overall, according to the FDA, approximately 2,000 people have been using Adcetris since its approval.

About the Consumer Justice Foundation

The Consumer Justice Foundation, whose Web site can be found at, is a for-profit organization that serves two purposes for consumers: (1) to provide educational information regarding the policies and procedures of large corporations and how they affect the average consumer; and (2) to provide news updates and resources that continue to update consumers regarding developments taken by corporations that include pharmaceutical drug companies, auto manufacturers and insurance companies so that consumers who have been harmed can use these informational resources to connect to an experienced professional who can help them. The team at the Consumer Justice Foundation is staffed by experienced and passionate consumer advocates whose mission is to raise the awareness of issues that could pose a risk of harm to those who may not otherwise be aware of the dangers they face.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Faith Anderson
Visit website